The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma.
about
The role of RANK-ligand inhibition in cancer: the story of denosumabIntegrating diet and exercise into care of prostate cancer patients on androgen deprivation therapyContemporary approaches for imaging skeletal metastasisProstate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastasesBisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell linePI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cellsA systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma.Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate CarcinomaEvolving role of bone biomarkers in castration-resistant prostate cancer.WITHDRAWN: Cardamonin Inhibits Osteoclastogenesis Induced by Tumor Cells Through Interruption of the Signaling Pathway Activated by Receptor Activator of NF-κB Ligand.Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathwayThe science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumorsRANKL signaling and osteoclastogenesis is negatively regulated by cardamoninMatrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue.Identification of beta-2 as a key cell adhesion molecule in PCa cell neurotropic behavior: a novel ex vivo and biophysical approach.Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer.Bony metastases: assessing response to therapy with whole-body diffusion MRI.Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trialIntravenous therapies for castration-resistant prostate cancer: toxicities and adverse events.A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.Anti-IL-20 Monoclonal Antibody Suppresses Prostate Cancer Growth and Bone Osteolysis in Murine Models.Developing imaging strategies for castration resistant prostate cancerThe use of zoledronic acid in Japanese men with stage D2 prostate cancer.Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis.PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancerShort-term outcomes of en bloc resection of solitary bone metastases in limbs.Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.Understanding and targeting osteoclastic activity in prostate cancer bone metastases.Unmet needs in the prediction and detection of metastases in prostate cancer.Design and methods for a Scandinavian pharmacovigilance study of osteonecrosis of the jaw and serious infections among cancer patients treated with antiresorptive agents for the prevention of skeletal-related events.Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.Denosumab: A comprehensive review.Imaging metastatic bone disease from carcinoma of the prostateThe osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer.Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis.Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine.Non-Mono-Exponential Analysis of Diffusion-Weighted Imaging for Treatment Monitoring in Prostate Cancer Bone Metastases.Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacy.False-positive diagnosis of disease progression by magnetic resonance imaging for response assessment in prostate cancer with bone metastases: A case report and review of the pitfalls of images in the literature
P2860
Q24633284-1C1F194B-9C5B-4558-AE8B-04EBB026B340Q26738281-E7B894F3-5E18-440D-8098-F830EA243276Q26798170-F99D074F-6D54-490F-BB7A-9AD20C3827CEQ28247245-433D4B4C-5240-4E3E-8E37-65046E935F1BQ28361973-E8B10651-5CA5-4184-8143-0CE2CDA82A49Q28395725-033492A3-9C8A-47A1-98D5-E8879C024973Q33581390-C69397BE-5BED-45AF-94AA-704F80B2FA62Q33584215-D3F1E236-4639-4F01-B7C9-91BA7A7F218EQ34023877-7CC48491-716D-47E6-AAA2-B244AE81B7B5Q34241611-B1454C60-031F-4296-96AA-032F882AFC29Q34279869-506F6D1B-985D-4967-91B5-6D0582B18BDDQ34617864-E2E6E389-B86C-4A2D-9685-DF06BDB41290Q34731280-4ECF3408-C839-4832-B7DC-D4380FA19E8AQ35083825-E20A112F-9D59-46D4-A5C0-B8E09413AA0FQ35180664-91840EB6-4BD1-4941-96AC-F4294719F552Q35598954-36658C8E-455A-495F-9CB4-6A49C3F2FEF8Q35697593-61C36453-1DC2-41B9-8752-C7F9C2C8544BQ35704399-39C2EF90-E3DE-4DEC-95E4-27DF7C1B960DQ35742655-3BC9253B-F1BD-4BA6-9541-9D7B95900026Q36108572-38390123-E405-4F37-A4D6-6BE902504AA1Q36126224-6B968CBF-A15C-4C11-BB99-4D3B42718D3BQ36152211-7297D011-D7A0-4A85-987F-510D375B7976Q36216856-4CF94E73-ABFE-45A0-B1A2-A4A92543696FQ36402883-E3F04C9E-41A0-46CE-9384-932390AB0010Q36493144-D7F11530-B1B8-436B-BDF9-2E817F9C07A8Q36576977-20A93B26-FC45-43F3-A5D8-5F247560A74AQ36723297-E342B46C-8862-418D-9EB4-CCD078DD1B6FQ36759374-3FD9F65C-B34B-4D42-980B-9CBD3D7D6066Q36871680-6BD28776-E90D-42FE-93F9-0A30B97A5175Q37123301-E5B94BCF-7773-46A4-BB3A-1736A6FC366DQ37131738-01753FAB-9E5D-4AC0-B526-44DA39F7D10FQ37467278-8072C2E4-0871-4ECD-BC25-2E0B041E49F2Q37605543-4F98B457-8657-4F41-AD00-78555C89952FQ37615017-9C76D7C9-3225-4DEE-AFD0-E6C475287D7AQ37926896-0BC22F29-963C-4D4A-ADFD-11029C4C5340Q38413261-22979E8C-36AF-4003-9F97-FE4046CB4AF4Q38479113-267A72DF-9A0E-467F-882A-C3FA930D5A4AQ38671355-139370AE-65FE-46D2-A244-8F612293E5EEQ38676999-19F22D15-31D1-4ABC-9D74-A5862FA8AEFCQ38703685-DBFA9B90-CA2D-41B0-9AF6-800C3118BD21
P2860
The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The natural history, skeletal ...... ients with prostate carcinoma.
@ast
The natural history, skeletal ...... ients with prostate carcinoma.
@en
type
label
The natural history, skeletal ...... ients with prostate carcinoma.
@ast
The natural history, skeletal ...... ients with prostate carcinoma.
@en
prefLabel
The natural history, skeletal ...... ients with prostate carcinoma.
@ast
The natural history, skeletal ...... ients with prostate carcinoma.
@en
P1433
P1476
The natural history, skeletal ...... ients with prostate carcinoma.
@en
P2093
Andriole GL
P304
P356
10.1002/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.3.CO;2-H
P407
P433
P577
2000-06-01T00:00:00Z